Canine Mendelian disease record

Neuronal Ceroid Lipofuscinosis 4A (Discovered in the American Staffordshire Terrier; NCL4A)

Q: How well studied is Neuronal Ceroid Lipofuscinosis 4A (Discovered in the American Staffordshire Terrier; NCL4A) in dogs?

OMIA curates 18 peer-reviewed references for Neuronal Ceroid Lipofuscinosis 4A (Discovered in the American Staffordshire Terrier; NCL4A). The full, linked citation list is on this page.

Neuronal Ceroid Lipofuscinosis 4A (Discovered in the American Staffordshire Terrier; NCL4A). Autosomal recessive. Observed in 8 of 266 breeds tested in the Sniff Atlas, with measured carrier frequencies drawn from 242,599 dogs (Donner 2023). Per-dog phenotype outcome depends on penetrance, modifiers, and environment; the carrier frequencies below describe variant prevalence, not disease incidence.

OMIA identifier: OMIA:001503-9615
Inheritance: Autosomal recessive
Variant pathogenicity: Pathogenic
Source dataset: Sniff Atlas v1.0.1 / DOI

The Pathogenic grade describes the documented variant's causality, per the Animal Variant Classification Guidelines (AVCG; Boeykens et al. 2024, Front Vet Sci), an ACMG/AMP-style framework curated in OMIA. It grades the variant, not any individual dog. See the full classification table.

About this disease

From OMIA's curated record

Documented in OMIA (Online Mendelian Inheritance in Animals). This describes the disease as recorded in the published literature, not a prediction for any individual dog. As of 2026-06-03.

Summary

Dogs with this lysosomal storage disorder have late-onset and slowly progressive behavioral changes, cognitive and motor degeneration, ataxia, seizures, and premature death.

Clinical features

Signs include late onset and slowly progressive behavioral changes, cognitive and motor degeneration, ataxia, seizures, and premature death. Kick et al. (2025) report retinal function deficits in affected American Staffordshire Terriers.

Molecular genetics

Abitbol et al. (2010) reported a likely causative mutation in American Staffordshire Terriers as a c.296G>A transition in the gene encoding the lysosomal enzyme arylsulfatase G. The variant leads to the p.R99H substitution in the protein. Affected dogs are deficient in ARSG. Nolte et al. (2016) reported the same variant in another affected American Staffordshire Terrier.

Pathology

Lysosomal storage inhibits intracellular and membrane trafficking, autophagy, and calcium storage, impair vesicle formation, and leads to premature neuronal apoptosis (Abitbol et al., 2010, Bellettato et al., 2010). Lesions include severe cerebellar cortical abiotrophy and remodeling with loss of Purkinje cells. Remaining Purkinje cells contain autofluorescent cytoplasmic storage material.

Prevalence

In populations in the USA and France, 50% of American Staffordshire Terriers tested were carriers (Abitbol et al., 2010).

History

The disease was first described as cerebellar cortical abiotrophy (Hanzliek et al., 2003) and cerebellar cortical degeneration (Olby et al., 2004; Buijtels et al. 2006) in American Staffordshire Terriers (see also OMIA000177-9615). Abitbol et al. (2010) reported a likely causative mutation for this disease in the ARSG gene and suggested - based on clinical signs and histopathology - that the disease is a neuronal ceroid lipofuscinosis with adult onset. However, Abitbol et al. (2010) did not identify the type of storage material. ARSG codes for arylsulfatase G, a lysosomal enzyme that functions in the degradation of heparan sulfate. Transgenic mice with ARSG deficiency were diagnosed with a mucopolysaccharidosis (Kowalewski et al., 2012, 2014, 2015) and it is likely that this lysosomal storage disorder in American Staffordshire Terriers is a mucopolysaccharidosis (Katz et al., 2017).

Control

Relatives to affected dogs should be tested. Avoid breeding affected dogs. Carriers should be bred only to noncarriers.

Genetic testing

A test is available.

Human analog

OMIA links this condition to the human gene record in OMIM (Mendelian Inheritance in Man), the place to read across to the deeper human literature for the same biology.

Gene · OMIM 610008

Source: OMIA (Nicholas, Tammen & the Sydney Informatics Hub), entry OMIA:001503-9615, doi:10.25910/2AMR-PV70 (CC-BY 4.0).

The evidence

Published references

The peer-reviewed papers behind this disease, curated by OMIA. Starred entries are OMIA-designated landmark papers. Showing 6 of 18.

Retinal function deficits in American Staffordshire Terriers with a late-onset neurodegenerative disease associated with an ARSG variant. · Vet Sci · 2025 · PMID 41295716
An overview of canine inherited neurological disorders with known causal variants. · Animals (Basel) · 2023 · PMID 38003185
Cerebellar ataxia in a young dog. · J Am Vet Med Assoc · 2023 · PMID 37290756
Phenotypic and genetic aspects of hereditary ataxia in dogs. · J Vet Intern Med · 2023 · PMID 37341581
Canine models of inherited musculoskeletal and neurodegenerative diseases. · Front Vet Sci · 2020 · PMID 32219101
Canine neuronal ceroid lipofuscinoses: Promising models for preclinical testing of therapeutic interventions. · Neurobiol Dis · 2017 · PMID 28860089

References curated by OMIA (Nicholas, Tammen & the Sydney Informatics Hub), doi:10.25910/2AMR-PV70 (CC-BY 4.0). Full list at the OMIA entry.

Predict a litter

Set each parent's status for Neuronal Ceroid Lipofuscinosis 4A (Discovered in the American Staffordshire Terrier; NCL4A) and see the odds for their puppies. Single recessive variant, exact Mendelian math.

Parent A

Parent B

NNClear

NmCarrier

mmAffected

Clear25%

Carrier50%

Affected25%

These are the genetic odds for one known variant, not a promise: a real litter varies around them, and penetrance or other genes can change whether the condition ever appears. Use it to avoid pairing two carriers and to keep a line healthy, not to engineer a dog. Inheritance mode per OMIA.

Your breed

See what Neuronal Ceroid Lipofuscinosis 4A (Discovered in the American Staffordshire Terrier; NCL4A) looks like in your dog's breed.

Carrier frequency by breed

Top 8 well-sampled breeds (n ≥ 50)

Maximum carrier frequency per breed across variants in the Donner 2023 cohort, with Wilson 95% confidence intervals. The list below is split into well-sampled breeds (n ≥ 50 tested) and small-sample breeds (n < 50, where the Wilson CI typically spans more than 20 percentage points and frequencies should not be compared directly to the well-sampled entries). Frequencies are population-level, not per-litter or per-line.

0%3%5%

American Staffordshire Terrier3.4% · n 42,746

3.4%n 42,746

Bulldog American0.28% · n 540

0.28%n 540

Rhodesian Ridgeback0.15% · n 323

0.15%n 323

Boston Terrier<0.1% · n 3,702

<0.1%n 3,702

Bulldog Standard<0.1% · n 4,815

<0.1%n 4,815

Boxer<0.1% · n 4,557

<0.1%n 4,557

Labrador Retriever<0.1% · n 16,854

<0.1%n 16,854

Border Collie<0.1% · n 6,712

<0.1%n 6,712

n = 80,249 dogs · Donner et al. 2023 carrier-screening cohort · Sniff Atlas

Each bar is one well-sampled breed; the whisker is its Wilson 95% CI, and fainter bars have wider intervals. Frequencies are population-level, not per-litter. Carrier status for Neuronal Ceroid Lipofuscinosis 4A (Discovered in the American Staffordshire Terrier; NCL4A) is measured; phenotype outcome depends on penetrance and modifiers.

▸ Full table with Wilson 95% confidence intervals

Breed	Carrier frequency	Wilson 95% CI	n tested
American Staffordshire Terrier	3.4%	[3.3%, 3.6%]	42,746
Bulldog American	0.28%	[0.1%, 1.2%]	540
Rhodesian Ridgeback	0.15%	[0.0%, 1.5%]	323
Boston Terrier	<0.1%	[0.0%, 0.2%]	3,702
Bulldog Standard	<0.1%	[0.0%, 0.1%]	4,815
Boxer	<0.1%	[0.0%, 0.1%]	4,557
Labrador Retriever	<0.1%	[0.0%, 0.0%]	16,854
Border Collie	<0.1%	[0.0%, 0.1%]	6,712

258 additional breeds in the Donner 2023 cohort were tested but showed no carriers.

Penetrance

From genotype to phenotype

Carrier status is not the same as disease status. Penetrance is the fraction of at-risk dogs that develop the phenotype. The Donner 2023 S4 table tracks this for 1 variant(s) underlying this disease in the cohort.

At-risk dogs evaluated: 2
Phenotype confirmed: 1
Penetrance range: not yet quantifiable

Predicted disease relevance at the per-dog level is UNPROVEN. The carrier frequency is measured; phenotype outcome is governed by penetrance, environment, and modifier loci. Consult a veterinarian for clinical interpretation.

How to cite this record

If you use this record in published work, cite the Sniff Atlas (the published dataset that carries the breed-level carrier frequencies) and the upstream sources:

Sniff Atlas v1.0.1 for the per-breed carrier frequencies:
Gehring, M. (2026). Sniff Atlas v1.0.1. Zenodo. https://doi.org/10.5281/zenodo.20566358. CC-BY 4.0.
OMIA for the disease definition, inheritance, and gene assignment:
Nicholas, F. W., & Tammen, I. (2024). OMIA. Sydney Informatics Hub, The University of Sydney. https://doi.org/10.25910/2AMR-PV70. Entry: OMIA:001503-9615.
Donner et al. 2023 for the breed × variant carrier-frequency cohort:
Donner, J., Freyer, J., Davison, S., Anderson, H., Blades, M., Honkanen, L., et al. (2023). Genetic prevalence and clinical relevance of canine Mendelian disease variants in over one million dogs. PLOS Genetics, 19(2), e1010651. https://doi.org/10.1371/journal.pgen.1010651.

Full citation formats (BibTeX, RIS, CITATION.cff) at sniff.world/cite.

Sniff Atlas v1.0.1, the source dataset for these frequencies.
Browse breeds, per-breed Mendelian profiles, including this disease in context.
OMIA entry OMIA:001503-9615, authoritative clinical reference.
About OMIA, the catalogue this record comes from, and how Sniff uses it.

Last updated June 20, 2026

Sources: Sniff Atlas v1.0.1 · OMIA OMIA:001503-9615 · Donner et al. 2023